University of Sheffield scientists have discovered that a drug that has been in use for a long time to treat liver disease could be effective in slowing down the progression of Parkinson’s disease.
Published in Neurology, the study demonstrated the benficial effects of UDCA on the nerve cells affected in Parkinson’s disease.
It is encouraging that, even at low concentrations the liver drug still affected the Parkinson’s cells grown in the lab. Given that UDCA is already approved for other purposes, this could allow the fast-tracking of testing to enable a treatment to be available for Parkinson’s in years rather than in decades – whilst also saving hundreds of millions in drug development costs.
The source article is available at: http://www.neurology.org/content/early/2015/08/07/WNL.0000000000001905.short
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo.